» Articles » PMID: 16136165

Enhanced Transduction of Mouse Bone Marrow-derived Dendritic Cells by Repetitive Infection with Self-complementary Adeno-associated Virus 6 Combined with Immunostimulatory Ligands

Overview
Journal Gene Ther
Date 2005 Sep 2
PMID 16136165
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

The potential of adeno-associated virus (AAV)-based vectors in human gene therapy is being explored for several diseases. Although sustained transgene expression and low vector-associated cellular immunity are attractive features of recombinant (r) AAV, the wider application of rAAV vectors encapsidated in serotype 2 capsid is hampered by poor transduction efficiency in many target tissues. These include ex vivo-generated dendritic cells (DC), which have demonstrated promising immunotherapeutic activity. We report here that efficient transduction of mouse bone marrow-derived DC can be achieved with self-complementary (sc) rAAV encapsidated in serotype 6 capsid. Sequential exposure of DC precursor cultures to IL-4 and GM-CSF with sc rAAV6 encoding the human tumor antigen, carcinoembryonic antigen (CEA), for 7 days followed by activation with CpG oligodeoxynucleotides (ODN) and anti-mouse CD40 antibody resulted in highly efficient transduction of DC. DC surface markers as determined by flow cytometry analysis of sc rAAV6-transduced DC were comparable to nontransduced DC. Efficiency of vector transduction and transgene expression were confirmed by immunostaining and real-time PCR. Microarray analysis of RNA from CpG ODN and CD40 antibody stimulated sc AAV6-transduced DC revealed upregulation of transcription factors and cytokines involved in immune activation and downregulation of inhibitory factors, suggesting a possible role of transcriptional activation in the observed effect. The adoptive transfer into syngeneic mice of the ex vivo-transduced and activated DC resulted in the development of CEA-specific antibody and T-helper 1-associated immune responses. Immunized mice also developed antibody to AAV6 capsid protein, which did not crossreact with AAV2 capsid protein. These studies demonstrate the potential utility of sc rAAV serotype 6-based vectors in transduction of DC for genetic vaccination approaches.

Citing Articles

Optimization of AAV vectors to target persistent viral reservoirs.

Colon-Thillet R, Jerome K, Stone D Virol J. 2021; 18(1):85.

PMID: 33892762 PMC: 8067653. DOI: 10.1186/s12985-021-01555-7.


Towards Clinical Implementation of Adeno-Associated Virus (AAV) Vectors for Cancer Gene Therapy: Current Status and Future Perspectives.

Hacker U, Bentler M, Kaniowska D, Morgan M, Buning H Cancers (Basel). 2020; 12(7).

PMID: 32674264 PMC: 7409174. DOI: 10.3390/cancers12071889.


Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans.

Gernoux G, Gruntman A, Blackwood M, Zieger M, Flotte T, Mueller C Mol Ther. 2020; 28(3):747-757.

PMID: 31982038 PMC: 7054721. DOI: 10.1016/j.ymthe.2020.01.004.


Transcriptional Profiles of Murine Bone Marrow-Derived Dendritic Cells in Response to Peste des Petits Ruminants Virus.

Li L, Wu J, Liu D, Du G, Liu Y, Shang Y Vet Sci. 2019; 6(4).

PMID: 31795377 PMC: 6958494. DOI: 10.3390/vetsci6040095.


An Engineered AAV6-Based Vaccine Induces High Cytolytic Anti-Tumor Activity by Directly Targeting DCs and Improves Ag Presentation.

Krotova K, Day A, Aslanidi G Mol Ther Oncolytics. 2019; 15:166-177.

PMID: 31720373 PMC: 6838889. DOI: 10.1016/j.omto.2019.10.001.